CSPG4 and melanoma: An early phase I clinical trial where an anti-idiotypic mAb MF11-30 against the 225.28 CSPG4-specific mAb clone was administered to 21 patients with stage IV melanoma reported complete remission in one patient and minor response in three other patients.